Evercore ISI Starts C.R. Bard, Inc. (BCR) at Buy

September 15, 2016 6:28 AM EDT
Get Alerts BCR Hot Sheet
Price: $218.92 -0.21%

Rating Summary:
    8 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade BCR Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Evercore ISI initiates coverage on C.R. Bard, Inc. (NYSE: BCR) with a Buy rating and a price target of $235.00.

Analyst Vijay Kumar commented, "The crux of thesis is that BCR is a high quality compounder within the Medical Device universe (above peer organic growth, consistent >100% free cash conversion and high ROIC), and expect the company to continue to maintain its multiple premium to S&P500 given its +5% organic visibility in the medium term (multiples have been correlated with organic rev growth vs. EPS & ROIC levels). While we acknowledge that Medtech multiples are stretched above their 5 year historical range, we believe that quality assets with sustainable growth will continue to outperform peers on a relative basis."

For an analyst ratings summary and ratings history on C.R. Bard, Inc. click here. For more ratings news on C.R. Bard, Inc. click here.

Shares of C.R. Bard, Inc. closed at $216.91 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Standard & Poor's

Add Your Comment